Changes in gene expression profiles in patients with pulmonary arterial hypertension associated with scleroderma treated with tadalafil

Seminars in Arthritis and Rheumatism

Volumn 46, Issue 4, 2017, Pages 465-472

  Cheong, Fei Ying ^a   Gower, Adam C ^a   Farber, Harrison W ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gene profiling; Pulmonary arterial hypertension; Scleroderma; Scleroderma associated pulmonary arterial hypertension; Systemic sclerosis

Indexed keywords

AMLODIPINE; BRAIN NATRIURETIC PEPTIDE; CYCLOPHOSPHAMIDE; DILTIAZEM; INTERLEUKIN 12; MYCOPHENOLATE MOFETIL; OXYGEN; TADALAFIL; VOLTAGE GATED POTASSIUM CHANNEL; PHOSPHODIESTERASE V INHIBITOR; TRANSCRIPTOME;

ADULT; ARTICLE; CARDIOPULMONARY HEMODYNAMICS; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DOWN REGULATION; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HUMAN; INNATE IMMUNITY; MALE; MIDDLE AGED; NEW YORK HEART ASSOCIATION CLASS; PILOT STUDY; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; SCLERODERMA; SIGNAL TRANSDUCTION; SIX MINUTE WALK TEST; TREATMENT OUTCOME; UPREGULATION; AGED; COMPLICATION; GENETICS; GOLGI COMPLEX; HYPERTENSION, PULMONARY; METABOLISM; MICROARRAY ANALYSIS; SYSTEMIC SCLEROSIS; WALK TEST;

AGED; DOWN-REGULATION; EXTRACELLULAR MATRIX; FEMALE; GOLGI APPARATUS; HUMANS; HYPERTENSION, PULMONARY; IMMUNITY, INNATE; INTERLEUKIN-12; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PHOSPHODIESTERASE 5 INHIBITORS; PILOT PROJECTS; POTASSIUM CHANNELS, VOLTAGE-GATED; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; TADALAFIL; TRANSCRIPTOME; TREATMENT OUTCOME; UP-REGULATION; WALK TEST;

EID: 84999780365     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2016.05.015     Document Type: Article

References (41)

1. [1] Montani, D., Chaumais, M.-C., Guignabert, C., Günther, S., Girerd, B., Jaïs, X., et al. Targeted therapies in pulmonary arterial hypertension. Pharmacol Ther 141 (2014), 172–191, 10.1016/j.pharmthera.2013.10.002.
2. [2] McLaughlin, V.V., Looking to the future: a new decade of pulmonary arterial hypertension therapy. Eur Respir Rev 20 (2011), 262–269, 10.1183/09059180.00006411.
3. [3] Ghofrani, H.-A., Galiè, N., Grimminger, F., Grünig, E., Humbert, M., Jing, Z.-C., et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 369 (2013), 330–340, 10.1056/NEJMoa1209655.
4. [4] Badesch, D.B., Tapson, V.F., McGoon, M.D., Brundage, B.H., Rubin, L.J., Wigley, F.M., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132 (2000), 425–434.
5. [5] Vij, R., Noth, I., Peripheral blood biomarkers in idiopathic pulmonary fibrosis. Transl Res J Lab Clin Med 159 (2012), 218–227, 10.1016/j.trsl.2012.01.012.
6. [6] Limited Systemic Sclerosis Patients With Pulmonary Arterial Hypertension Show Biomarkers of Inflammation and Vascular Injury. PubMed—NCBI, n.d. 〈http://www-ncbi-nlm-nih-gov.ezproxy.bu.edu/pubmed/20808962〉 [accessed 09.06.15].
7. [7] Interferon and Alternative Activation of Monocyte/Macrophages in Systemic Sclerosis-associated Pulmonary Arterial Hypertension. PubMed—NCBI, n.d. 〈http://www-ncbi-nlm-nih-gov.ezproxy.bu.edu/pubmed/21425123〉 [accessed 09.06.15].
8. [8] Irizarry, R.A., Hobbs, B., Collin, F., Beazer-Barclay, Y.D., Antonellis, K.J., Scherf, U., et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostat Oxf Engl 4 (2003), 249–264, 10.1093/biostatistics/4.2.249.
9. [9] Gautier, L., Cope, L., Bolstad, B.M., Irizarry, R.A., affy—analysis of Affymetrix GeneChip data at the probe level. Bioinforma Oxf Engl 20 (2004), 307–315, 10.1093/bioinformatics/btg405.
10. [10] Gentleman, R.C., Carey, V.J., Bates, D.M., Bolstad, B., Dettling, M., Dudoit, S., et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol, 5, 2004, R80, 10.1186/gb-2004–5–10-r80.
11. [11] Klipper-Aurbach, Y., Wasserman, M., Braunspiegel-Weintrob, N., Borstein, D., Peleg, S., Assa, S., et al. Mathematical formulae for the prediction of the residual beta cell function during the first two years of disease in children and adolescents with insulin-dependent diabetes mellitus. Med Hypotheses 45 (1995), 486–490.
12. [12] Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102 (2005), 15545–15550, 10.1073/pnas.0506580102.
13. [13] Subramanian, A., Kuehn, H., Gould, J., Tamayo, P., Mesirov, J.P., GSEA-P: a desktop application for gene set enrichment analysis. Bioinforma Oxf Engl 23 (2007), 3251–3253, 10.1093/bioinformatics/btm369.
14. [14] Hamaguchi, Y., Fujimoto, M., Hasegawa, M., Matsushita, T., Takehara, K., Bosentan increases serum IL-12 levels in systemic sclerosis patients with pulmonary arterial hypertension. J Dermatol Sci 55 (2009), 66–67, 10.1016/j.jdermsci.2009.02.013.
15. [15] Trinchieri, G., Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 84 (1994), 4008–4027.
16. [16] De Man, F.S., Tu, L., Handoko, M.L., Rain, S., Ruiter, G., François, C., et al. Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. Am J Respir Crit Care Med 186 (2012), 780–789, 10.1164/rccm.201203–0411OC.
17. [17] Willers, E.D., Newman, J.H., Loyd, J.E., Robbins, I.M., Wheeler, L.A., Prince, M.A., et al. Serotonin transporter polymorphisms in familial and idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 173 (2006), 798–802, 10.1164/rccm.200509–1361OC.
18. [18] Chung, W.K., Deng, L., Carroll, J.S., Mallory, N., Diamond, B., Rosenzweig, E.B., et al. Polymorphism in the angiotensin II type 1 receptor (AGTR1) is associated with age at diagnosis in pulmonary arterial hypertension. J Heart Lung Transplant 28 (2009), 373–379, 10.1016/j.healun.2009.01.016.
19. [19] Marcos, E., Fadel, E., Sanchez, O., Humbert, M., Dartevelle, P., Simonneau, G., et al. Serotonin transporter and receptors in various forms of human pulmonary hypertension. Chest 128 (2005), 552S–553S, 10.1378/chest.128.6_suppl.552S.
20. [20] Forfia, P.R., Mathai, S.C., Fisher, M.R., Housten-Harris, T., Hemnes, A.R., Champion, H.C., et al. Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med 177 (2008), 1364–1369, 10.1164/rccm.200712–1876OC.
21. [21] Becker, M.O., Kill, A., Kutsche, M., Guenther, J., Rose, A., Tabeling, C., et al. Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. Am J Respir Crit Care Med 190 (2014), 808–817, 10.1164/rccm.201403–0442OC.
22. [22] Pullamsetti, S.S., Savai, R., Janssen, W., Dahal, B.K., Seeger, W., Grimminger, F., et al. Inflammation, immunological reaction and role of infection in pulmonary hypertension. Clin Microbiol Infect 17 (2011), 7–14, 10.1111/j.1469–0691.2010.03285.x.
23. [23] Cohen-Kaminsky, S., Hautefort, A., Price, L., Humbert, M., Perros, F., Inflammation in pulmonary hypertension: what we know and what we could logically and safely target first. Drug Discov Today, 2014, 10.1016/j.drudis.2014.04.007.
24. [24] Rabinovitch, M., Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 122 (2012), 4306–4313, 10.1172/JCI60658.
25. [25] Schober, A., Zernecke, A., Chemokines in vascular remodeling. Thromb Haemost 97 (2007), 730–737.
26. [26] El Chami H, Hassoun PM. Immune and inflammatory mechanis. Prog Cardiovasc Dis. 2012. PubMed–NCBI, n.d. 〈http://www-ncbi-nlm-nih-gov.ezproxy.bu.edu/pubmed/23009917〉 [accessed 27.07.13].
27. [27] Ormiston, M.L., Chang, C., Long, L.L., Soon, E., Jones, D., Machado, R., et al. Impaired natural killer cell phenotype and function in idiopathic and heritable pulmonary arterial hypertension. Circulation 126 (2012), 1099–1109, 10.1161/CIRCULATIONAHA.112.110619.
28. [28] Smith, P., Heath, D., Electron microscopy of the plexiform lesion. Thorax 34 (1979), 177–186.
29. [29] Sehgal, P.B., Mukhopadhyay, S., Dysfunctional intracellular trafficking in the pathobiology of pulmonary arterial hypertension. Am J Respir Cell Mol Biol 37 (2007), 31–37, 10.1165/rcmb.2007–0066TR.
30. [30] Merkow, L., Kleinerman, J., An electron microscopic study of pulmonary vasculitis induced by monocrotaline. Lab Investig 15 (1966), 547–564.
31. [31] Mette, S.A., Palevsky, H.I., Pietra, G.G., Williams, T.M., Bruder, E., Prestipino, A.J., et al. Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy. Am Rev Respir Dis 145 (1992), 1196–1200, 10.1164/ajrccm/145.5.1196.
32. [32] Mukhopadhyay, S., Xu, F., Sehgal, P.B., Aberrant cytoplasmic sequestration of eNOS in endothelial cells after monocrotaline, hypoxia, and senescence: live-cell caveolar and cytoplasmic NO imaging. Am J Physiol Heart Circ Physiol 292 (2007), H1373–H1389, 10.1152/ajpheart.00990.2006.
33. [33] Lee, J.E., Patel, K., Almodóvar, S., Tuder, R.M., Flores, S.C., Sehgal, P.B., Dependence of Golgi apparatus integrity on nitric oxide in vascular cells: implications in pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol 300 (2011), H1141–H1158, 10.1152/ajpheart.00767.2010.
34. [34] Remillard, C.V., Tigno, D.D., Platoshyn, O., Burg, E.D., Brevnova, E.E., Conger, D., et al. Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension. Am J Physiol Cell Physiol 292 (2007), C1837–C1853, 10.1152/ajpcell.00405.2006.
35. [35] Chen, W.-L., Huang, X.-Q., Zhao, L.-Y., Li, J., Chen, J.-W., Xiao, Y., et al. Involvement of Kv1.5 protein in oxidative vascular endothelial cell injury. PloS One, 7, 2012, e49758, 10.1371/journal.pone.0049758.
36. [36] Archer, S.L., Gomberg-Maitland, M., Maitland, M.L., Rich, S., Garcia, J.G.N., Weir, E.K., Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1alpha-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer. Am J Physiol Heart Circ Physiol 294 (2008), H570–H578, 10.1152/ajpheart.01324.2007.
37. + channel gene transcription in primary pulmonary hypertension. Lancet 351 (1998), 726–727, 10.1016/S0140–6736(05)78495–6.
38. [38] Reeve, H.L., Michelakis, E., Nelson, D.P., Weir, E.K., Archer, S.L., Alterations in a redox oxygen sensing mechanism in chronic hypoxia. J Appl Physiol 90 (2001), 2249–2256.
39. [39] Wipff, J., Dieudé, P., Guedj, M., Ruiz, B., Riemekasten, G., Cracowski, J.L., et al. Association of a KCNA5 gene polymorphism with systemic sclerosis-associated pulmonary arterial hypertension in the European Caucasian population. Arthritis Rheum 62 (2010), 3093–3100, 10.1002/art.27607.
40. [40] Bossini-Castillo, L., Simeon, C.P., Beretta, L., Broen, J., Vonk, M.C., Callejas, J.L., et al. KCNA5 gene is not confirmed as a systemic sclerosis-related pulmonary arterial hypertension genetic susceptibility factor. Arthritis Res Ther, 14, 2012, R273, 10.1186/ar4124.
41. [41] Ma, L., Roman-Campos, D., Austin, E.D., Eyries, M., Sampson, K.S., Soubrier, F., et al. A novel channelopathy in pulmonary arterial hypertension. N Engl J Med 369 (2013), 351–361, 10.1056/NEJMoa1211097.